



OPEN ACCESS

EDITED AND REVIEWED BY
Tinghe Yu,
Chongqing Medical University, China

*CORRESPONDENCE

Jiankun Chen
✉ chenjiankunductor@126.com
Chengming Sun
✉ 18953569897@163.com
Yue Lu
✉ gzylyue@126.com

RECEIVED 09 June 2025

ACCEPTED 23 June 2025

PUBLISHED 07 July 2025

CITATION

Qu L, Xin Y, Feng J, Ren X, Li Z, Chen X,
Miao G, Chen J, Sun C and Lu Y (2025)
Correction: Downregulation of PRKCI
inhibits osteosarcoma cell growth by
inactivating the Akt/mTOR signaling pathway.
Front. Oncol. 15:1643772.
doi: 10.3389/fonc.2025.1643772

COPYRIGHT

© 2025 Qu, Xin, Feng, Ren, Li, Chen, Miao,
Chen, Sun and Lu. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License \(CC BY\)](#).
The use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Correction: Downregulation of PRKCI inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway

Liuqing Qu¹, Yu Xin², Jieni Feng³, Xiaolei Ren³, Zuming Li³,
Xueru Chen³, Guangyan Miao⁴, Jiankun Chen^{5*},
Chengming Sun^{1*} and Yue Lu^{6,7*}

¹Department of Clinical Laboratory, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China, ²Department of Medical Laboratory, Qingdao Sixth People's Hospital, Qingdao, China, ³The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China, ⁴Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, United States, ⁵The Third Comprehensive Department, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China, ⁶State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China, ⁷Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Guangzhou University of Chinese Medicine, Guangzhou, China

KEYWORDS

PRKCI, osteosarcoma, proliferation, Akt/mTOR signaling pathway, therapy

A Correction on

Downregulation of PRKCI inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway

By Qu L, Xin Y, Feng J, Ren X, Li Z, Chen X, Miao G, Chen J, Sun C and Lu Y (2024). *Front. Oncol.* 14:1389136. doi: 10.3389/fonc.2024.1389136

In the published article, there was an error in [Figure 5A](#) and [Figure 6A](#) as published. During an AI-assisted image integrity review of our published work, we identified inadvertent duplications in [Figure 5A](#) and [Figure 6A](#) (Migration, PRKCI and shcontrol; Wound healing assay, 0h shcontrol and shPRKCI, 24h Vector and shPRKCI). This was an oversight during figure preparation and does not affect the study's conclusions. We have since located the original data and prepared a corrected version of the figure. The corrected [Figure 5A](#) and [Figure 6A](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 5
The Transwell system was used to evaluate the effect of PRKCI on the migration and invasion of osteosarcoma cells. **(A, C)** Transwell migration assay and Matrigel invasion assay for SW1353 cells or U2OS cells after transfection empty vector or PRKCI plasmid for 24 h (shcontrol or shPRKCI for 48 h). Cells were stained with crystal violet (magnification: x200). **(B, D)** Quantification of invaded and migrated SW1353 cells or U2OS cells. (Data were based on three independent experiments and shown as the mean ± SEM, ***p* < 0.01).




FIGURE 6
A wound-healing assay was used to evaluate the effect of PRKCI on the migration of osteosarcoma cells. **(A, B)** Microscopic images of wound-healing assay data for SW1353 and U2OS cells transfected with empty vector or PRKCI plasmid for 24 h (*shcontrol* or *shPRKCI* for 48 h). (Data were based on three independent experiments and shown as the mean \pm SEM, ** $p < 0.01$).